Citius Pharmaceuticals (NASDAQ:CTXR – Get Free Report) and GlycoMimetics (NASDAQ:GLYC – Get Free Report) are both small-cap medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their analyst recommendations, institutional ownership, dividends, risk, valuation, profitability and earnings.
Analyst Recommendations
This is a breakdown of recent recommendations and price targets for Citius Pharmaceuticals and GlycoMimetics, as reported by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Citius Pharmaceuticals | 0 | 0 | 1 | 0 | 3.00 |
| GlycoMimetics | 0 | 0 | 2 | 0 | 3.00 |
Citius Pharmaceuticals presently has a consensus price target of $4.00, suggesting a potential upside of 410.79%. GlycoMimetics has a consensus price target of $10.00, suggesting a potential upside of 329.18%. Given Citius Pharmaceuticals’ higher possible upside, research analysts plainly believe Citius Pharmaceuticals is more favorable than GlycoMimetics.
Risk & Volatility
Insider & Institutional Ownership
16.9% of Citius Pharmaceuticals shares are held by institutional investors. Comparatively, 75.2% of GlycoMimetics shares are held by institutional investors. 15.0% of Citius Pharmaceuticals shares are held by company insiders. Comparatively, 8.7% of GlycoMimetics shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company is poised for long-term growth.
Profitability
This table compares Citius Pharmaceuticals and GlycoMimetics’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Citius Pharmaceuticals | N/A | -41.63% | -36.74% |
| GlycoMimetics | N/A | -73.09% | -64.38% |
Valuation & Earnings
This table compares Citius Pharmaceuticals and GlycoMimetics’ revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Citius Pharmaceuticals | N/A | N/A | -$32.54 million | ($0.26) | -3.03 |
| GlycoMimetics | $10,000.00 | 14,823.50 | -$36.90 million | ($0.58) | -3.97 |
Citius Pharmaceuticals has higher earnings, but lower revenue than GlycoMimetics. GlycoMimetics is trading at a lower price-to-earnings ratio than Citius Pharmaceuticals, indicating that it is currently the more affordable of the two stocks.
Summary
Citius Pharmaceuticals beats GlycoMimetics on 6 of the 10 factors compared between the two stocks.
About Citius Pharmaceuticals
Citius Pharmaceuticals, Inc., a late-stage pharmaceutical company, engages in the development and commercialization of critical care products focusing on oncology products, anti-infectives products in adjunct cancer care, prescription products, and stem cell therapy. It is developing five proprietary products comprising LYMPHIR, an engineered IL-2 diphtheria toxin fusion protein for the treatment of patients with persistent or recurrent cutaneous T-cell lymphoma, which is in Phase 3 clinical trial; Mino-Lok, an antibiotic lock solution to treat patients with catheter-related bloodstream infections by salvaging the infected catheter, which is in Phase 3 clinical trial; Halo-Lido, a corticosteroid-lidocaine topical formulation that intends to provide anti-inflammatory and anesthetic relief to persons suffering from hemorrhoids that is in clinical Phase 2b trial; Mino-Wrap, a liquifying gel-based wrap for reduction of tissue expander infections following breast reconstructive surgeries; and NoveCite, a mesenchymal stem cell therapy for the treatment of acute respiratory disease syndrome. The company was founded in 2007 and is headquartered in Cranford, New Jersey.
About GlycoMimetics
GlycoMimetics, Inc., a clinical-stage biotechnology company, focuses on the discovery and development of glycobiology-based therapies for cancers, including acute myeloid leukemia (AML) and inflammatory diseases with unmet needs in the United States. It is developing uproleselan, an E-selectin antagonist, which is used in combination with chemotherapy to treat AML, as well as in phase 3 trial to treat relapsed/refractory AML. The company also develops various other programs, including GMI-1687, an antagonist of E-selectin to treat vaso-occlusive crisis; and galectin-3 antagonists, a carbohydrate-binding protein. In addition, it is developing GMI-1359, which targets e-selectin and a chemokine receptor for the treatment of cancers that affect the bone and bone marrow, including solid tumors. The company has a cooperative research and development agreement with the National Cancer Institute; and a collaboration and license agreement with Apollomics (Hong Kong) Limited for the development and commercialization of uproleselan and GMI-1687. GlycoMimetics, Inc. was incorporated in 2003 and is headquartered in Rockville, Maryland.
Receive News & Ratings for Citius Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Citius Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
